COVID-19 Long Haulers (Long COVID) Treatment (Patented Rx Technology)

• There are approximately 12 million Americans with COVID-19 Long Hauler Symptoms that are at serious risk of developing Pulmonary Fibrosis.  Patients with Pulmonary Fibrosis have an increased risk and susceptibility to COVID-19 infection, which can reach a mortality rate of 50%.  
• In a Phase III Clinical Trial in Miami with COVID-19 Long Haulers, N115 Nasal Spray clinically and significantly reduced coughing/sneezing, reduced headaches and body aches, increased Sa02 levels, and improved breathing, as reported on clinicaltrials.gov.